Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Prostatic Neoplasms × darolutamide × Clear all

Phase

Phase 2 23 Phase 1 10 Phase 3 6 Phase 4 3 Phase 1/2 3 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Prednisone 4 Androgen Antagonists 4 Radiosurgery 3 gallium 68 PSMA-11 2 enzalutamide 2 bicalutamide 2 Zoledronic Acid 2 Triptorelin Pamoate 2 Mitoxantrone 2 Leuprolide 2 Goserelin 2 Celecoxib 2 Abiraterone Acetate 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 satraplatin 1 maltodextrin 1 luprolide acetate gel depot 1 genistein combined polysaccharide 1 darolutamide 1 cabazitaxel 1 abiraterone 1 abemaciclib 1 Vitamin D 1 Therapeutics 1 Tea 1 Tacrolimus 1 Standard of Care 1 Soybean Proteins 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06282588 2024-02-28

THUNDER

Cancer Research Antwerp

Phase 2/3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡